Insmed Provides Clinical Update on Phase 2b CEDAR Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/31/2026

1. AMZN
2. RBLX
3. AAPL
4. RDDT
5. COIN
6. NBIX
7. DXCM
8. GH
9. GDDY
10. WU

Go back to Insmed Provides Clinical Update on Phase 2b CEDAR Study
INSMED (NASDAQ: INSM) Delayed: 98.60 -2.89 (2.85%)
Previous Close $101.49    52 Week High $19.30 
Open $101.25    52 Week Low $9.02 
Day High $101.91    P/E N/A 
Day Low $97.05    EPS $-1.69 
Volume 2,902,596